TY - JOUR
T1 - Back to the future
T2 - Rethinking the great potential of lncrnas for optimizing chemotherapeutic response in ovarian cancer
AU - Elsayed, Abdelrahman M.
AU - Amero, Paola
AU - Salama, Salama A.
AU - Abdelaziz, Abdelaziz H.
AU - Lopez-Berestein, Gabriel
AU - Rodriguez-Aguayo, Cristian
N1 - Funding Information:
This research was funded by NIH through the Brain SPORE Career Enhancement Program and NCI grant: P50CA127001; NIH through the Ovarian SPORE Career Enhancement Program and NCI grant: P50CA217685, to Paola Amero and Cristian Rodriguez-Aguayo. Abdelrahman M. Elsayed was supported by the Egyptian Ministry of Higher Education (EMHE). We thank Bryan Tutt in Editing Services, Research Medical Library at MD Anderson Cancer Center for critical reading of the manuscript.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/9
Y1 - 2020/9
N2 - Ovarian cancer (OC) is one of the most fatal cancers in women worldwide. Currently, platinum-and taxane-based chemotherapy is the mainstay for the treatment of OC. Yet, the emergence of chemoresistance results in therapeutic failure and significant relapse despite a consistent rate of primary response. Emerging evidence substantiates the potential role of lncRNAs in determining the response to standard chemotherapy in OC. The objective of this narrative review is to provide an integrated, synthesized overview of the current state of knowledge regarding the role of lncRNAs in the emergence of resistance to platinum-and taxane-based chemotherapy in OC. In addition, we sought to develop conceptual frameworks for harnessing the therapeutic potential of lncRNAs in strategies aimed at enhancing the chemotherapy response of OC. Furthermore, we offered significant new perspectives and insights on the interplay between lncRNAs and the molecular circuitries implicated in chemoresistance to determine their impacts on therapeutic response. Although this review summarizes robust data concerning the involvement of lncRNAs in the emergence of acquired resistance to platinum-and taxane-based chemotherapy in OC, effective approaches for translating these lncRNAs into clinical practice warrant further investigation.
AB - Ovarian cancer (OC) is one of the most fatal cancers in women worldwide. Currently, platinum-and taxane-based chemotherapy is the mainstay for the treatment of OC. Yet, the emergence of chemoresistance results in therapeutic failure and significant relapse despite a consistent rate of primary response. Emerging evidence substantiates the potential role of lncRNAs in determining the response to standard chemotherapy in OC. The objective of this narrative review is to provide an integrated, synthesized overview of the current state of knowledge regarding the role of lncRNAs in the emergence of resistance to platinum-and taxane-based chemotherapy in OC. In addition, we sought to develop conceptual frameworks for harnessing the therapeutic potential of lncRNAs in strategies aimed at enhancing the chemotherapy response of OC. Furthermore, we offered significant new perspectives and insights on the interplay between lncRNAs and the molecular circuitries implicated in chemoresistance to determine their impacts on therapeutic response. Although this review summarizes robust data concerning the involvement of lncRNAs in the emergence of acquired resistance to platinum-and taxane-based chemotherapy in OC, effective approaches for translating these lncRNAs into clinical practice warrant further investigation.
KW - Chemotherapy
KW - Dysregulated expression
KW - Long non-coding RNAs
KW - Mechanisms of resistance
KW - Ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=85090603362&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090603362&partnerID=8YFLogxK
U2 - 10.3390/cancers12092406
DO - 10.3390/cancers12092406
M3 - Review article
C2 - 32854207
AN - SCOPUS:85090603362
SN - 2072-6694
VL - 12
SP - 1
EP - 35
JO - Cancers
JF - Cancers
IS - 9
M1 - 2406
ER -